Related references
Note: Only part of the references are listed.Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2020)
Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
Cynthia Huang Bartlett et al.
PLOS ONE (2020)
Breast Cancer Treatment A Review
Adrienne G. Waks et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-world data: towards achieving the achievable in cancer care
Christopher M. Booth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Assessment of quality of life (QoL) in breast cancer patients by using EORTC QLQ-C30 and BR-23 questionnaires: A tertiary care center survey in the western region of Saudi Arabia
Muhammad Imran et al.
PLOS ONE (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy
Sung Pil Hong et al.
NATURE COMMUNICATIONS (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
S. Nolte et al.
EUROPEAN JOURNAL OF CANCER (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park et al.
LANCET ONCOLOGY (2019)
The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor
Lorenzo Dottorini et al.
JOURNAL OF GERIATRIC ONCOLOGY (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Pedram Razavi et al.
CANCER CELL (2018)
Expanding the Evidence Base in Geriatric Oncology: Action Items From an FDA-ASCO Workshop
Laura A. Levit et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
Markus Wallwiener et al.
JOURNAL OF MEDICAL INTERNET RESEARCH (2017)
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Nicholas C. Turner et al.
LANCET (2017)
Targeted Therapies in Older Adults With Breast Cancer: What Do We Know?
Shlomit Strulov Shachar et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
NCCN Guidelines Update: Breast Cancer
William Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Breast Cancer in Women Older Than 80 Years
Shlomit Strulov Shachar et al.
JOURNAL OF ONCOLOGY PRACTICE (2016)
Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement
Arti Hurria et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Debu Tripathy et al.
BMC CANCER (2014)
Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
D. A. Yardley et al.
BRITISH JOURNAL OF CANCER (2014)
Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial
Angelo Di Leo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care
Sarah L. Elson et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2012)
Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
Peter A. Kaufman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
Jonas Bergh et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Rita S. Mehta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
Adam M. Brufsky et al.
CLINICAL CANCER RESEARCH (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Quality-of-life in elderly patients with cancer:: A short review
Ulrich Wedding et al.
EUROPEAN JOURNAL OF CANCER (2007)
Activities of daily living in women with advanced breast cancer
Susan DeSanto-Madeya et al.
ONCOLOGY NURSING FORUM (2007)
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
PL Toogood et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials
AB Kornblith et al.
CANCER (2002)
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
JGM Klijn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
